Fresenius Completes Peru Divestment
Fresenius Completes Peru Divestment
Dow JonesApr 23 03:01 ET
CVS Favors Humira Copycats Hurting AbbVie's Market Share: Evercore
Seeking AlphaApr 17 09:26 ET
Becton, Dickinson Boosts Syringe Production Amid FDA Concerns on Supplies
Seeking AlphaMar 21 10:22 ET
Fresenius Settles With Johnson & Johnson to Market Stelara Alternative
By David Sachs Pharmaceutical companies Fresenius Kabi and Formycon have reached a settlement with Johnson & Johnson to commercialize a Crohn's Disease drug in Europe and Canada. Fresenius said Mond
WSJMar 18 05:36 ET
Fresenius Supervisory Board Extends Contract of Chief Financial Officer Sara Hennicken
Fresenius Supervisory Board Extends Contract of Chief Financial Officer Sara Hennicken
Dow JonesMar 8 03:03 ET
Fresenius: Contract Extention Runs to 2027
Fresenius: Contract Extention Runs to 2027
Dow JonesMar 8 03:03 ET
Novo Nordisk Slips, Dialysis Stocks Gain After Kidney Disease Data for Ozempic
Seeking AlphaMar 5 07:30 ET
Fresenius Appoints Sustainability Advisory Board
Fresenius Appoints Sustainability Advisory Board
Dow JonesFeb 27 02:35 ET
Fresenius Shares Rise After Better-Than-Expected Results
By Nina Kienle Fresenius shares rose after the company posted better-than-expected adjusted earnings and organic revenue growth for the fourth quarter and raised its cost-savings target for next year
WSJFeb 21 05:44 ET
Fresenius Guidance Looks Conservative -- Market Talk
0908 GMT - Fresenius's guidance looks conservative at first glance after the company posted better-than-expected fourth-quarter results, Citi analysts say in a research note. The German healthcare com
WSJFeb 21 04:09 ET
Analysts Saw Fresenius 4Q EBIT Before Special Items at EUR590.7M
Analysts Saw Fresenius 4Q EBIT Before Special Items at EUR590.7M
Dow JonesFeb 21 01:02 ET
Fresenius 4Q EBIT EUR85M
Fresenius 4Q EBIT EUR85M
Dow JonesFeb 21 01:02 ET
Fresenius Expects 2024 EBIT Growth of 4%-8% at Constant Currency
Fresenius Expects 2024 EBIT Growth of 4%-8% at Constant Currency
Dow JonesFeb 21 01:02 ET
Fresenius Raises 2025 Savings Target to EUR400M From EUR350M
Fresenius Raises 2025 Savings Target to EUR400M From EUR350M
Dow JonesFeb 21 01:02 ET
Fresenius Won't Propose Dividend for 2023 as Previously Announced
Fresenius Won't Propose Dividend for 2023 as Previously Announced
Dow JonesFeb 21 01:02 ET
Fresenius: 4Q Net Loss Mainly Results From Deconsolidation of Fresenius Medical Care
Fresenius: 4Q Net Loss Mainly Results From Deconsolidation of Fresenius Medical Care
Dow JonesFeb 21 01:02 ET
Fresenius: Cost-Savings Target for 2023 Significantly Exceeded
Fresenius: Cost-Savings Target for 2023 Significantly Exceeded
Dow JonesFeb 21 01:02 ET
Fresenius 4Q Organic Revenue Growth Was 5%
Fresenius 4Q Organic Revenue Growth Was 5%
Dow JonesFeb 21 01:02 ET
Fresenius Completes Divestment of Fertility Services Group Eugin
Fresenius Completes Divestment of Fertility Services Group Eugin
Dow JonesJan 31 10:39 ET
Fresenius Suspends 2023 Dividend After Using German Relief Package
By Adria Calatayud Fresenius suspended dividends and management bonuses for 2023 after it decided to retain governmental compensation and reimbursement payments of up to 300 million euros ($324 milli
Dow JonesDec 6, 2023 01:26 ET
No Data
No Data